Chicago, United States
Evozyne, founded in 2020, is at the forefront of the Biotechnology and Pharmaceutical industries with its innovative approach to drug development. The company's slogan, "Generative AI-powered drug discovery platform and product development," encapsulates its mission to design novel protein therapeutics that meet previously unmet patient needs.
Headquartered in the United States, Evozyne employs cutting-edge technologies to revolutionize the way protein therapeutics are discovered and developed. This approach not only accelerates the drug discovery process but also enhances the potential for tackling complex, untreated health challenges.
In its recent Series B investment, Evozyne secured a substantial $81.00M in funding on 01 September 2023 from top investors, including Valor Equity Partners, OrbiMed, Paragon Biosciences, nVentures, and Fidelity Investments. This infusion of capital is expected to propel the company's growth and expand its capabilities in developing groundbreaking therapeutics that address critical patient needs.
SilicoGenesis